Cardlytics Exceeds Q4 Revenue Forecasts, Adjusted EBITDA Rises
CDLX is trading near its 52-week low of $0.751 (9.0% above the low).
Summary
Cardlytics reported Q4 revenue of $56.10 million, surpassing analyst estimates of $54.45 million, despite a 24.2% year-over-year decline. The company also demonstrated improved profitability, with adjusted EBITDA increasing by $2.1 million compared to the prior year, a narrower net loss, and positive free cash flow. Additionally, Cardlytics provided Q1 2026 guidance, projecting revenue between $35 million and $40 million and adjusted EBITDA between $(7.5) million and $(3.5) million. For a micro-cap company, beating revenue expectations and showing a clear path to improved financial health, particularly in profitability metrics, is a significant positive development that could attract investor interest and potentially impact its stock price. Traders will be watching how the market reacts to the Q1 guidance and the company's ability to sustain profitability improvements.
At the time of this announcement, CDLX was trading at $0.82 on NASDAQ in the Technology sector, with a market capitalization of approximately $48.7M. The 52-week trading range was $0.75 to $3.28. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.